Sareum Holdings plc

LSE:SAR.L

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United Kingdom

Market Cap

USD 25.90 M

Share Price

USD 0.19

Avg Daily Volume

649,627

Change (1 day)

-2.86%

Change (1 year)

-59.89%

Change (YTD)

-37.14%

Sareum Holdings plc Revenue for the year ending June 30, 2024: USD 0.00

Sareum Holdings plc Revenue is USD 0.00 for the year ending June 30, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Sareum Holdings plc Revenue for the year ending June 30, 2023 was USD 0.00.
Sareum Holdings plc Revenue for the year ending June 30, 2022 was USD 0.00.
Sareum Holdings plc Revenue for the year ending June 30, 2021 was USD 0.00, a -100.00% change year over year.
Sareum Holdings plc Revenue for the year ending June 30, 2020 was USD 58.53 K.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

LSE: SAR.L

Sareum Holdings plc

CEO	Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
IPO Date	Oct. 11, 2004
Location	United Kingdom
Headquarters	Langford Arch
Employees	5
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.